

Day 1	Policy and Epidemiology				
07.00	Registration				
08.30 - 12.30	Opening Ceremony and Session A: How do we Work Together to Achieve HCV Elimination Among People who Inject Drugs? Room: Sala I + II Chairs: Rui Tato Marinho, Hospital Santa Maria; Medical School of Lisbon; Portuguese Society of Gastroenterology, Portugal; Jeffrey Lazarus, ISGlobal; Hospital Clínic; University of Barcelona, Spain; Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal; Luís Mendão, GAT, Portugal				
08.0 - 08.45	Welcome to the Symposium				
08.45 - 09.30	Policy Opening and Report from Policy Day Ricardo Baptista Leite, Member of Parliament, Portuguese National Parliament, Portugal				
09.30 - 09.35	Opening from European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) Alexis Goosdeel, European Monitoring Centre for Drugs and Drug Addiction, (EMCDDA), Portugal				
09.35 - 09.45	Community Opening and Report from Community Summit Eberhard Schatz, Correlation Network, Amsterdam; Magda Ferreira, GAT, Portugal				
09.45 - 09.55	Awards				
09.55 - 10.00	IJDP Tim Rhodes, London School of Hygiene and Tropical Medicine and Editor-in-Chief for the International Journal of Drug Policy, United Kingdom				
10.00 - 10.30	Coffee Break and Poster Viewing				
10.30 - 12.30	Session A continued Room: Sala I + II Chairs: Judy Chang, Daniel Simões & Margaret Hellard				
10.30 - 10.50	Successes and Challenges of Drug Policy in Portugal: Decriminalization is not Enough João Goulão, General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), Portugal				
10.50 - 11.10	What will it Take to Achieve the HCV Elimination Goals Among People who Inject Drugs? Annette Verster, World Health Organization, Switzerland				
11.10 - 11.20	Questions & Discussion				
11.20 - 11.30	Is it All They Said it Would Be? Drug Users Experience of Portuguese Decriminalisation Rui Miguel Coimbra Morais, Consumers Associated Survive Organised (CASO)				
11.30 - 11.40	Rewriting the Policy Narrative: Hepatitis C and a Right to Health James Dunne, Australian Injecting & Illicit Drug Users League (AIVL), Vienna				
11.40 - 12.00	Panel Discussion: Humanising Efforts to Reach People who Inject Drugs: Decriminalisation, Rights and Health Panelists: Rui Miguel Coimbra Morais, Consumers Associated Survive Organised (CASO), Portugal; James Dunne, Australian Injecting & Illicit Drug Users League (AIVL), Vienna; Jude Byrne, Australian Injecting & Illicit Drug Users League (AIVL), Australia; João Goulão, General-Directorate for Intervention on Addictive Behaviours and				
12.00 - 12.15	Sexualised Drug Use and Co-Occurring High Risk Behaviours Among Gay and Bisexual Men Living with HIV/Hepatitis C Co-infection in Melbourne, Australia Brendan Harney, Alfred Health & Burnet Institute, Australia				
12.15 - 12.30	Opiate Agonist Therapy and Prevention of HCV Transmission Among People who Inject Drugs: The Importance of Clinically-Indicated and Patient-Perceived Dosage Adequacy Andrea Adelina Arteni, Université De Montréal, Canada				
12.30 - 14.00	Lunch and Poster Viewing				
12.45 - 13.45	Lunch Symposium: Shaping Tomorrow Together: Insights from Experience Room: Sala I + II				
14.00 - 15.15	Session B: Epidemiology of HCV Infection Room: Sala XII + XIII Chairs: Jennifer Havens & Vivian Hope	14.00 - 15.15	Session C: Efforts to Enhance HCV Diagnosis and Testing Room: Sala II Chairs: Jude Byrne & Ryan Westergaard	14.00 - 15.15	Session D: Models of Care for HCV Infection Room: Sala I Chairs: Mojca Matičič & Phillip Read
14.00 - 14.15	Estimating the Number of People who Inject Drugs in Athens, Greece: Implications for the Burden of Hepatitis C Infection and the Coverage of Harm Reduction Programs Sotirios Roussos, University Of Athens, Greece	14.00 - 14.15	Client and Staff Perspectives on Point-of-Care Hepatitis C Testing for People Attending Needle Syringe Programs Ned Latham, Burnet Institute, Australia	14.00 - 14.15	Community Outreach Events – Engaging the Disengaged Julie Holeksa, Vancouver Infectious Diseases Centre, Canada
14.15 - 14.30	Increased Risk of Hepatitis-C Virus and Skin and Soft Tissue Infection Among People Who Inject Novel Psychoactive Substances Andrew McAuley, Glasgow Caledonian University, United Kingdom	14.15 - 14.30	Factors Associated with HCV Testing Among People who Inject Drugs in an Urban Setting in Vietnam Giang Le, Hanoi Medical University, Vietnam	14.15 - 14.30	The Kombi Clinic Driving Out Hep C in South East Queensland Disenfranchised Communities Joss O'Loan, Kombi Clinic, Australia
14.30 - 14.45	Combined Coverage of Harm Reduction Interventions and Rates of Primary and Recurrent HCV Infection in a Community-Based Cohort of People Who Inject Drugs Nanor Minoyan, CRCHUM / Université De Montréal, Canada	14.30 - 14.45	Hepcatt (Hepatitis C Assessment To Treatment Trial) in Primary Care: A Cluster RCT of Whether a Complex Intervention Based on Risk Prediction Algorithm Tool and Education Can Increase Testing and Diagnosis of HCV in Primary Care Matthew Hickman, Population Health Sciences, Bristol Medical School, United Kingdom	14.30 - 14.45	Hepatitis C Screening and Linkage to Care at Four New York City Syringe Exchange Programs Nirah Johnson, NYC Department Of Health And Mental Hygiene, United States
14.45 - 14.50	Exposing the Need for Viral Hepatitis C Services for People who Inject Drugs in South Africa: Findings from a Three-City Cross Sectional Survey Andrew Scheibe, TB HIV Care, South Africa	14.45 - 14.50	Linking Hepatitis C Infection People who Inject Drugs to Treatment and Care, South Africa Angela McBride, Out Well-being, Harmless Project, South Africa	14.45 - 14.50	An Onsite Primary Care Based Approach Allows Rapid Reduction of Hepatitis C Prevalence in Prison. A Case Study From Canberra, Australia Michael Levy, ACT Justice Health Service, Australia

14.50 - 14.55	Increase in HCV Prevalence Among People who Inject Drugs in Ukraine Tetiana Saliuk, Alliance For Public Health, Ukraine	14.50 - 14.55	High Prevalence of Current and Past Hepatitis C Virus Infections Among New Injectors Found in a Cross-Sectional Study in Germany, 2011-2014: Missed Opportunities for Counselling and Testing Julia Enkelmann, Robert Koch Institute, Germany	14.50 - 14.55	The Road to Hepatitis C Elimination: A Change in Care Pathway Increases Access to Hepatitis C Treatment for People on Opiate Substitution Therapy Brian Stephens, NHS Tayside, United Kingdom
14.55 - 15.00	Factors Associated with Hepatitis C in HIV Positive Men who Have Sex with Men Pablo Ryan, Infanta Leonor Hospital, Spain	14.55 - 15.00	The National Stigma Indicator Project: Key Findings and Lessons Regarding People Living with HCV and People who Inject Drugs Carla Treloar, University of New South Wales, Australia	14.55 - 15.00	Implementation of Routine HIV/HCV Screening and Linkage to Care in the Idea Exchange; Miami, FL Tyler Bartholomew, University of Miami, United States
15.00 - 15.05	Correlations Between Injecting Frequency and Housing Stability Trajectories Evolving Concomitantly Over One Year: Results from a Cohort Study of People who Inject Drugs in Montréal, Canada Emmanuel Fortier, CHUM Research Centre, Canada	15.00 - 15.05	Despite High Risk Behaviors, Including Chemsex, Barriers Exist for HCV Testing in MSM Throughout India Brianna Norton, Montefiore Medical Center, United States	15.00 - 15.05	A Community-Based Model of Peer-Led Anonymous Rapid Hepatitis C (HCV) Testing for People who Inject Drugs (PWIDs) in Mauritius Arnaud Nicolas Patrick Manbode, PILS, Mauritius
15.05 - 15.10	Housing Stability and Hepatitis C Infection for Young Adults who Inject Drugs: Meghan Morris, University Of California, San Francisco, United States	15.05 - 15.10	People who Inject Drugs have Inequitable Chance to be HCV Tested Lulia Novak, ICF, Alliance for Public Health, Ukraine	15.05 - 15.10	A Responsive Model of Care Utilizing a Collaborative Nurse Practitioner and Peer Based Model of Care Leanne Myers, Peer Based Harm Reduction WA, Australia
15.10 - 15.15	Attenuated Protective Effect of Opioid Agonist Therapy on Hepatitis C Incidence Among Females Kimberly Page, University Of New Mexico, United States	15.10 - 15.15	Hepatitis C Testing, Treatment Uptake and Sustained Virologic Response Among Gay and Bisexual Men with Hepatitis C and HIV Co-Infection in Melbourne, Australia Alisa Pedrana, Burnet Institute, Australia	15.10 - 15.15	Health Prevention Delegate: Visiting General Practitioners and Pharmacists in the Pyrénées Atlantiques Area (France) Cecilia Maitre, Resapsad, France
15.15 - 16.15	Coffee Break & Poster Tour				
16.15 - 17.45	Session E: Epidemiology and Public Health Room: Sala I Chairs: Sarah Larney & Jennifer Havens	16.15 - 17.30	Session F: Integration of HCV, Other Co-Infections and Harm Reduction Services (CHAFAEA Sponsored Session) Room: Sala XII + XIII Chairs: Jean Luc Sion & Jeffrey Lazarus	16.15 - 17.30	Session G: Monitoring HCV elimination among PWID (EMCDDA sponsored session) Room: Sala II Chairs: Jane Mounteney & Antons Mozalevskis
16.15 - 16.35	Epidemiology of HCV Infection Among People who Inject Drugs: Where do we Really Need to Focus Our Efforts to Eliminate HCV Globally? Matthew Hickman, University of Bristol, United Kingdom	16.15 - 16.20	What Does the EU Mean by "Integrated" Infectious Disease Programmes and what Policy Developments have there Been to Further this Agenda? Jean Luc Sion, DG SANTE, Portugal	16.15 - 16.30	Monitoring the Elimination of HCV as a Public Health Threat Among People who Inject Drugs in the EU Thomas Seyler, EMCDDA, Portugal
		16.20 - 16.25	Integration of HCV, Other Co-Infections and Harm Reduction Services for People Who Inject Drugs in Portugal João Goulão, General-Directorate for Intervention on Addictive Behaviours and Dependencies (SICAD), Portugal		
16.35 - 16.55	Will HCV Reinfection Compromise Our Elimination Efforts? Gregory Dore, Kirby Institute, University of New South Wales, Australia	16.25- 16.35	How do EU Agencies take an Integrated Approach to Hepatitis C Control Dagmar Hedrich, European Monitoring Centre for Drugs and Drug Addiction, (EMCDDA), Portugal	16.30 - 16.45	Model Projections of the Impact of HCV Treatment on Chronic HCV in European Settings Hannah Fraser, University of Bristol, United Kingdom
		16.35 - 16.45	Best Practice Model from a Czech Republic Prison Viktor Mravčík, National Monitoring Centre for Drugs and Addiction, Czech Republic	16.45 - 17.00	HCV Elimination in Dutch People who use Drugs? The 5 Steps of the National Hepatitis Plan Esther Croes, Trimbos Instituut, Belgium
16.55 - 17.45	Panel: Concrete priorities and actions that will be required to eliminate hepatitis C infection among people who use drugs? Panellists: Matthew Hickman, University of Bristol, United Kingdom; Gregory Dore, Kirby Institute, University of New South Wales, Australia; Judy Chang, INPUD; Magda Ferreira, GAT Portugal			17.00 - 17.15	Towards HCV Elimination in People who Inject Drugs in Slovenia: How to Monitor a Real-Life Situation? Moica Maticic, University of Ljubljana, Ukraine
		16.45 - 17.00	Transitioning Specialist HCV Services into the Community John (Jack) Jack Lambert, Hep-CARE, United Kingdom; Alistair Story, E-DETECT, United Kingdom	17.15 - 17.20	Progress and Challenges in Monitoring Elimination Among People who Inject Drugs Ruth Zimmermann, Robert Koch Institute Berlin, Germany
		17.00 - 17.45	What Does Integration of Services for People who Inject Drugs Mean in Terms of Testing and Providing Treatment? How Does the Health Systems Need to Change to Better Integrate and can it? Can we Eliminate Hepatitis C Among People who Inject Drugs on Opioid Substitution Therapy in the Near Future? Panellists: Jeffrey Lazarus, HA-REACT, Spain; John (Jack) Lambert, Hep-Care, INTEGRATE, United Kingdom; Alistair Story, E-DETECT TB, United Kingdom, Raquel Duarte, Porto Integrated PWID Centre, Portugal; Viktor Mravčík, National Monitoring Centre for Drugs and Addiction, Czech Republic	17.20 - 17.45	Questions & Discussion
17.45 - 19.00	Welcome Reception & Poster Viewing				

Day 2	HCV Diagnosis, Linkage to Care and Treatment				
07.30	Registration				
08.00 - 08.45	Breakfast Symposium: A Personalised Approach to HCV Treatment: It's not just About the Virus Room: Sala I + II				
09.00 - 10.45	Session H: Enhancing the HCV Care Cascade Room: Sala I + II Chairs: Anne Øvrehus and Joseph Doyle				
09:00 - 09:20	Point-of-care Testing and Diagnostics for HCV Infection: Have we Reached a Single-visit Diagnosis? Karine Lacombe, Sorbonne-Universités, Inserm - APHP, France				
09:20 - 09:40	Strategies to Foster Task-shifting and Broaden Models of HCV Prevention and Care John Dillon, University of Dundee, United Kingdom				
09:40 - 10:00	Strategies to Facilitate Linkage to Care for People Who Inject Drugs in Low and Middle Income Countries Shruti Mehta, John Hopkins Bloomberg School of Public Health, United States				
10.00 - 10.15	Questions & Discussion				
10:15 - 10:30	Rural Risk Environment For Hepatitis C Among Young Adults Who Use Opioids In Appalachian Kentucky David Cloud, Emory University, Rollins School Of Public Health, United States				
10.30 - 10.45	Cost-Effectiveness Analysis of Testing Strategies for Diagnosing Hepatitis C Virus Infection in People Who Inject Drugs in Resource-Constrained Countries Léa Duchesne, Inserm, France				
10.45 - 11.15	Coffee Break and Poster Viewing				
11.15 - 12.15	Session I: Workshops				
	Is it Cirrhosis? Is it Cancer? A Practical Guide Room: Sala XIII	11.15 - 12.15	Meaningful Patient And Public Involvement In HCV Research: A Focus On Peer Researchers Room: Sala XII		
	Rui Tato Marinho, Hospital Santa Maria; Medical School of Lisbon; Portuguese Society of Gastroenterology, Portugal		Emma Hamilton, Scottish Drugs Forum, United Kingdom		
11.15 - 12.15	Session J: Epidemiology, Modelling and Cost-Effectiveness Room: Sala II Chairs: Vana Sypsa & Natasha Martin	11.15 - 12.15	Session K: Addressing Gaps to Improve HCV Treatment Access Room: Sala I Chairs: Tim Rhodes & Tessa Windelinckx		
11.15 - 11.30	The Cost-Effectiveness of Undertaking HCV Treatment in Needle and Syringe Programmes in Tayside, Scotland Zoe Ward, University Of Bristol, United Kingdom	11.15 - 11.30	Do National HCV Policies in the EU Address Treatment and Care for People Who Inject Drugs? Stine Neilsen, Freelance, Spain		
11.30 - 11.45	Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs in Nairobi Jack Stone, University Of Bristol, United Kingdom	11.30 - 11.45	Barriers and Facilitators of Hepatitis C (HCV) Treatment Initiation Among People Who Inject Drugs in the Era of New Direct Acting Antivirals Iuliia Makarenko, McGill University, Canada		
11.45 - 12.00	Cost-Effectiveness of Scaling-Up Syringe Service Provision Among People Who Inject Drugs In Perry County, Kentucky Hannah Fraser, University Of Bristol, United Kingdom	11.45 - 12.00	W3 Framework: Understanding the Role And Quality of Peer Led Programs by People Who Inject Drugs in a National Hepatitis C Response Graham Brown, Australian Research Centre In Sex, Health And Society, La Trobe University, Australia		
12.00 - 12.05	Estimation of the Number of People who Inject Drugs and Live With HIV and Viral Hepatitis Co-Infection in Ukraine Kostyantyn Dumchev, Ukrainian Institute on Public Health Policy, Ukraine	12.00 - 12.05	Knowledge Around Direct Acting Antiviral Therapies and Willingness to Undergo HCV Treatment Among Rural Appalachian Opioid Users Jennifer Havens, University Of Kentucky College Of Medicine, United States		
12.05 - 12.10	The Results of HIV and HCV Prevention Program Among People Who Inject Drugs in Ukraine Tetiana Mykhalchuk, Alliance For Public Health, Ukraine	12.05 - 12.10	Attitude of Staff Regarding Integrated Hepatitis C Treatment at Eight Harm Reduction Centers in Georgia Lasha Gulbiani, Health Research Union, Georgia		
12.10 - 12.15	A Cost-Effective Strategy to Reach the WHO Hepatitis C Virus (HCV) Elimination Target in Men Who Have Sex With Men in the UK : A 90% Decrease in Hepatitis C Incidence By 2030 Peter Vickerman, University Of Bristol, United Kingdom	12.10 - 12.15	Integrating Hepatitis C Care for At-Risk Groups: Findings from a Multi-Centre Observational Study in Primary and Community Care Eithne Nic An Ríogh, University College Dublin, Ireland		
12.15 - 13.45	Lunch and Poster Viewing				
12.30 - 13.30	Lunch Symposium: Striving for HCV Elimination – High-Risk Populations, High Reward? Room: Sala I + II				
13.45 - 15.00	Session L: Enhancing the HCV Care Cascade Room: Sala XII + XIII Chairs: Amy Nunn & Behzad Hajarizadeh	13.45 - 15.00	Session M: Strategies to Improve HCV Treatment Outcomes Room: Sala I Chairs: Nina Weis & Håvard Midgard	13.45 - 15.00	Session N: Models of Care for HCV Infection (Sponsored by IAS) Room: Sala II Chairs: Alexandra King & Jorge Mera
13.45 - 14.00	Conceptualising Access in the DAA Era: Applying the Candidacy Framework to Inform Research and Practice in HCV Care for People Who Use Drugs Stine Høj, Centre de Recherche du CHUM, Canada	13.45 - 14.00	Preliminary Analysis of the Superdot-C Study: a Cluster Randomised Controlled Trial of Pharmacy Led Versus Conventional Treatment for HCV Positive Patients Receiving Daily Opioid Substitution Therapy Within NHS Scotland Andrew Radley, National Health Service Tayside, United Kingdom	13.45 - 14.00	A Multi-Sectoral Model to Support Hepatitis C Testing and Treatment Access Among People Who Inject Drugs in Hanoi, Vietnam Thuy Ma Thu, Medecins Du Monde - Vietnam Mission, Vietnam
14.00 - 14.15	Hepatitis C Virus (HCV) Testing, Liver Disease Assessment and Direct-Acting Antiviral (DAA) Treatment Uptake and Outcomes in a Homeless Service in Sydney, Australia: the Liverlife Study Sahar Bajis, The Kirby Institute, University Of New South Wales, Australia	14.00 - 14.15	The Treatment as Prevention Approach Results in an Early and Marked Reduction in Prevalence of Hepatitis C Viremia Among People With Recent Injection Drug Use. Results from the Treatment as Prevention (TRAP HEPC) Program in Iceland Valgerdur Runarsdottir, SAA Addiction Clinics, Iceland	14.00 - 14.15	Daily Dosing of Direct Acting Antivirals (DAA) from a Public Opioid Substitution Treatment (OST) Program for Marginalised Clients in Kings Cross, Sydney Phillip Read, Kirkeaton Road Centre, Australia

14.15 - 14.30	Straight to the Point – Lessons from the Rapid-EC Study: a Point-Of-Care Hepatitis C Testing Pilot in Needle and Syringe Programs Targeted to People Who Inject Drugs in Australia Alisa Pedrana, Burnet Institute, Australia	14.15 - 14.30	Engaging People Who Inject Drugs in Community Based Treatment and Care Using a Nurse-Led, Social Network Model Sally Von Bibra, The Burnet Institute, Australia	14.15 - 14.30	Indigenous Led Hepatitis C Treatment Model to Achieve Elimination in Big River First Nation Stuart Skinner, University of Saskatchewan, Canada & Charlene Gardiner, Big River First Nation, Canada
14.30 - 14.35	Improving HCV Treatment Uptake in Prison: Breaking the 60-Day Barrier Zameer Mohamed, Imperial College London, United Kingdom	14.30 - 14.35	Use of Simplified HCV Testing, Diagnosis and Generic Sofosbuvir/Velpatasvir Treatment Leading to 100% SVR12 in Myanmar (USAID/EQUIP Project) Yin Min Thauung, Community Partners International, Myanmar	14.30 - 14.35	Accelerating the Hepatitis C Care Cascade for Patients with Substance Use Jessica Rienstra, Lummi Tribal Health Center, United States
14.35 - 14.40	Improving Engagement with Healthcare in Hepatitis C: a Randomised Controlled Trial of a Peer Advocacy Intervention Marie Francis, University College London, United Kingdom	14.35 - 14.40	“Lost to Follow up” Patients Have Equivalent Sustained Viral Response Rates to Patients Attending their Scheduled SVR12 Visit. Alison Boyle, NHS Greater Glasgow and Clyde, United Kingdom	14.35 - 14.40	The Cascade of HCV Care Among People Who Inject Drugs in a Norwegian Low-Threshold Setting: Increasing Treatment Uptake Øystein Backe, The Hepatitis C Clinic, Norway
14.40 - 14.45	Mobile Community-Based Liver Health Assessment in Underserved Populations: The Hepcare Project Julian Surey, University College London, United Kingdom	14.40 - 14.45	Hepatitis C Treatment in People Who Inject Drugs on Medication Assisted Therapy Versus People Attending a Needle Exchange Program NCT03093415 Andrew Seaman, Oregon Health & Sciences University, United States	14.40 - 14.45	Difficult Venous Access: Addressing this Barrier to Care in Hepatitis Treatment Clinics Sinead Sheils, Institution, Australia
14.45 - 14.50	Reinfection Following HCV DAA Therapy Among People Who Inject Drugs on Opioid Agonist Therapy: the Prevail Study Matthew Akiyama, Montefiore Medical Center	14.45 - 14.50	HCV Cure Rates Among People Who Inject Drugs not Receiving Medication Assisted Treatment in an American Indian/Alaskan Native Population Whitney Essex, Cherokee Nation Health Services, United States	14.45 - 14.50	Treatment of Hepatitis C in a Cohort of Former and Current Injecting Drug Users in Nairobi, Kenya Dmytro Donchuk, Médecins Sans Frontières, Belgium
14.50 - 14.55	Universal On-Site HCV-RNA Screening is Warranted Among Active People Who Inject Drugs Who Attend Harm Reduction Centres in Catalonia, Spain (HepCdetect II Study) Elisa Martró, Germans Trias I Pujol University Hospital And Research Institute (IGTP), Barcelona	14.50 - 14.55	Collocation of Buprenorphine with HCV Treatment to Improve Adherence and Reduce Harm in People Who Inject Drugs with HCV: Update from the ANCHOR Study Sarah Kattakuzhy, University Of Maryland School Of Medicine, United States	14.50 - 14.55	END hepC-NM: a Collaborative Approach Towards Hepatitis C Elimination in a Resource Scarce Environment Kim Page, University of New Mexico, United States
14.55 - 15.00	Uptake of Treatment for Hepatitis C Infection in People Who Inject Drugs: the Link Study Rob Bielen, Hasselt University, Belgium	14.55 - 15.00	HCV Cascade of Care at an Integrated Community Facility for People who Inject Drugs Leith Morris, School Of Public Health, University Of Queensland, Australia	14.55 - 15.00	RECAP: an Interprofessional Comprehensive Community-based Care Clinic for the Management of Hepatitis C Positive and At-Risk Individuals in Saint John, New Brunswick, Canada Sarah Gander, Horizon Health, Canada
15.00 - 15.30 Coffee Break & Poster Tour					
15.30 - 17.20	Session O: Harm Reduction and HCV Prevention Room: Sala I Chairs: Eberhard Schatz & Dagmar Hedrich	15.30 - 17.20	Session P: Challenges for enhancing HCV care among PWID in low and middle income countries (sponsored by IAS and MDM) Room: Sala II Chairs: Niklas Luhmann & Edo Agustian	15.30 - 17.00	Session Q: Diagnostics Room: Sala XII + Sala XIII Chairs: Tanya Applegate & Christian Ramers
15.30 - 15.50	Novel HCV Prevention Strategies for People Who Inject Drugs Patrizia Carrieri, Aix Marseille Université, INSERM, France	15.30 - 15.50	Together in Harm Reduction: Synergizing Efforts Between HIV and Hepatitis Programmes Sarah Hess, World Health Organisation, Switzerland	15.30 - 15.50	Enhancing Hepatitis C and HIV Testing Using Rapid Diagnostic Antibody Testing in Marginalized Populations Amy Nunn, Brown University, United States
15.50 - 16.10	State of the Art on Drug Treatment Julie Bruneau, Université de Montréal, Canada	15.50 - 16.10	Improving Access to Care for People Who Inject Drugs in Kenya: From Pilot Study to National Programme Abigael Lukhwaro, Médecins du Monde, Kenya	15.50 - 16.10	Point-of-care Finger-stick Hepatitis C RNA Testing: Broadening Access to Testing in the Community Tanya Applegate, The Kirby Institute, University of New South Wales Sydney, Australia
16.10 - 16.50	Supervised Injecting Sites, Drug Consumption Rooms and Overdose Prevention: Where do we Stand in 2018? Joan Colom, Public Health Agency of Catalonia, Spain Gabi Becker, Geschäftsführerin der Integrativen Drogenhilfe Frankfurt, Germany Ricardo Fuentes, City of Lisbon, Portugal Adriana Curado, GAT, Portugal Dirk Schäffer, Deutsche Aids Hilfe, Germany	16.10 - 16.30	Successful Community-led Efforts to Enhance HCV Prevention, Testing and Linkage to Care Among People Who Inject Drugs in Low and Middle-income Countries Edo Agustian, Asian Network of People who Use Drugs (ANPUD)/PKNI, Asia	16.10 - 16.20	Hepatitis C Testing from Dried Blood Spots: Simplifying Testing to Broaden Community-Based Screening John Dillon, University of Dundee, Scotland
16.50 - 17.20	Questions & Discussion	16.30 - 16.50	The Cost of Diagnostics Annette Gaudino, Treatment Action Group, United States	16.20 - 16.40	Enhancing Diagnostic Access in Low and Middle-income Countries Emmanuel Fajardo, Médecins Sans Frontières, Spain
		16.50 - 17.20	Questions & Discussion	16.40 - 17.00	Panel Discussion
19:00 - 23:00 Symposium Dinner					

Day 3	HCV treatment and access
09.00 - 09.45	Breakfast Symposium: Exploring New Models of Care with Decentralised HCV RNA Testing Room: Sala I + II
10.00 - 12.00	Session R: Management of HCV in People Who Inject Drugs Room: Sala I + II Chairs: Rui Tato Marinho and Lynn Taylor
10.00 - 10.20	Direct-Acting Antiviral Therapy: Have we Reached Perfectovir for People Who Inject Drugs? Brian Conway, Vancouver ID Centre, Canada
10.20 - 10.40	Management of Advanced Liver Disease and Risk of HCC Massimo Colombo, University of Milan, Italy
10.40 - 11.00	Life Beyond SVR - It is not Just About SVR: the Clinical Benefits of Successful DAA Therapy Beyond Cure Alessio Aghemo, Humanitas Research Hospital, Italy
11.00 - 11.20	Life Beyond SVR - It is not Just About SVR: the Social Benefits of Successful DAA Therapy Beyond Cure Carla Treloar, Centre for Social Research in Health, UNSW Sydney, Australia
11.20 - 11.30	Questions & Discussion
11.30 - 11.45	Adherence to Sofosbuvir and Velpatasvir Among People with Chronic HCV Infection and Recent Injection Drug Use: the SIMPLIFY Study Evan Cunningham, The Kirby Institute, Australia
11.45 - 12.00	Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs: a Systematic Review and Meta-Analysis Behzad Hajarizadeh, University Of New South Wales, Australia
12.00 - 12.45	Coffee Break & Poster Tour
12.00 - 12.45	Session S: We aren't Hard to Reach if You Know How Room: Sala I + II Chairs: Jude Byrne & Daniel Simões
12.00 - 12.05	User Driven HCV Clinic on 4 Wheels Ole Jørgen Lygren, Prolamett, Norway
12.05 - 12.10	Furthering the Hepatitis C Diagnosis Process to Easy Access and Comprehensive Coverage. Janjira Lintong, TTAG, Thailand
12.10 - 12.15	Models of Care - From Patient to Organizer of Community Testing Anja Plener Bloch, Brugernes Akademy, Denmark
12.15 - 12.20	Meaningful Involvement of Indonesian Drugs User Network in Respond and Availability HCV treatment Access in Indonesia Andika Wibaskara, Indonesian Drugs User Network, (PKNI), Indonesia
12.20 - 12.45	Panel Discussion
12.45 - 13.45	Lunch
13.00 - 13.45	INHSU GAM

13.45 - 14.45	Session T: HCV Reinfection Room: Sala XII + XIII Chairs: Stefan Christensen & Sarah Kattakuzhy	13.45 - 14.45	Session U: It is Not Always Just About HCV: Drug User Health and HCV Room: Sala I Chairs: Kathryn Leafe & Suzanne Brissette	13.45 - 14.45	Session V: Models of Care for HCV Infection Room: Sala II Chairs: Monica Sousa & Martin Kåberg
13.45 - 14.00	High Re-Infection Rates Among People Who Inject Drugs Successfully Treated for Hepatitis C in a Community Needle and Syringe Programme Jasmine Schulkind, University Bristol, United Kingdom	13.45 - 14.00	Care Beyond the Virus: Engaging the Most Marginalised in Hepatitis C Care Magdalena Harris, London School Of Hygiene & Tropical Medicine, United Kingdom	13.45 - 14.00	Experience and Outcomes of a High Volume Homeless Health Center-Based HCV Treatment Program in Boston Marguerite Beiser, Boston Health Care For The Homeless, United States
14.00 - 14.15	Reinfection and Retreatment: Attitudes Among Prisoner Participants from the Australian SToP-C Study Jake Rance, Centre For Social Research In Health, Australia	14.00 - 14.15	Sex, Drugs and HCV: The Role of Sex and Sex Work in Hepatitis C Virus Infection Among People who Inject Drugs in Montréal Brendan Jacka, CHUM Research Centre, Canada	14.00 - 14.15	Treating People Where They Are: Micro-elimination in Practice Tamara Barnett & Karen Lundgren, Cool Aid Community Health Centre, Canada
14.15 - 14.30	Reinfection Following Successful HCV DAA Therapy Among People with Recent Injecting Drug Use: The SIMPLIFY and D3FEAT Studies Evan Cunningham, The Kirby Institute, University of New South Wales, Australia	14.15 - 14.30	Preliminary Analysis of the Prime Study; a Randomized Controlled Trial Comparing the Hepatitis C Care Cascade in Primary Care Vs. Tertiary Care Margaret Hellard, Burnet Institute, Australia	14.15 - 14.30	Building Bridges to Eliminate HCV in People Who Inject Drugs: Knowledge and Planned Performance Change Among HCV Treeters and Addiction-services Providers Engaged in a Pilot Education Initiative Jody Gilmore, Penn Presbyterian Medical Center, United States
14.30 - 14.35	Drug Use and Reinfection During and Following Hepatitis C Virus (HCV) Treatment With Elbasvir/Grazoprevir (EBR/GZR) Among Patients Receiving Opioid Agonist Therapy (OAT): the C-Edge Co-Star Study Gregory Dore, Kirby Institute, University of New South Wales, Australia	14.30 - 14.35	Changes in Drug and Alcohol Use and Injection Risk Behaviours Among People Who Inject Drugs During and Following HCV Direct-Acting Antiviral Treatment: the SIMPLIFY and D3FEAT Studies Andreea Adelina Artenie, Université de Montréal, Canada	14.30 - 14.35	Liberating Medeco-Inala from Hep C. a Study of Micro-Elimination in Primary Care Matthew Young, Medeco-Inala, Australia
14.35 - 14.40	Low HCV Reinfection Rate After Treatment in People Who Inject Drugs (PWID) from a Prospective Cohort in Tbilisi, Georgia Tamar Kikvidze, Médecins Du Monde, France	14.35 - 14.40	Real-World Data on Safety and Effectiveness of Glecaprevir/Pibrentasvir for the Treatment of Patients With Chronic Hepatitis C Virus Infection on Opioid Substitution Therapy: Latest Results from the German Hepatitis C-Registry Jens Reimer, Universitätsklinikum Hamburg-Eppendorf, Germany	14.35 - 14.40	Chronic Hepatitis C Eradication Model Through Primary Care in British Columbia, Canada John Farley, Dr. John Farley Inc., Canada
14.40 - 14.45	Low Rate of Reinfection Following Direct-Acting Antiviral HCV Treatment Among People with Recent Injecting Drug Use: a Real-Life Experience Håvard Midgard, Oslo University Hospital, Norway	14.40 - 14.45	Treatment Outcomes Achieved With All-Oral Hepatitis C Treatment in People Who Currently Inject Drugs: a Systematic Review and Meta-Analysis Ned Latham, Burnet Institute, Australia	14.40 - 14.45	Hepatitis C Care in an Opioid Substitution Treatment Unit Simon Larsson, Sahlgrenska University Hospital, Sweden
14.45 - 15.15 Coffee Break					
15.15 - 16.30	Session X: Enhancing access to HCV care for PWID Room: Sala XII + XIII Chairs: Américo Nave & Erin O'Mara	15.15 - 16.30	Session Y: Enhancing HCV prevention and treatment in prisons Room: Sala I + II Chairs: Nadine Kronfli & Andrew Lloyd		
15.15 - 15.35	Advocacy for affordable access to DAA therapy from the community perspective: Lessons from Malaysia Yatie Jonet, Malaysian AIDS Council, Malaysia	15.15 - 15.35	Needle and Syringe Programmes for HCV Prevention in Prisons: Where do we Stand Globally? Rick Lines, Hilary Rodham Clinton School of Law, Swansea University, United Kingdom		
15.35 - 15.55	Working Towards Addressing Stigma Erin O'Mara, European Network of People who Use Drugs, United Kingdom	15.35 - 15.55	Enhancing Access to HCV Testing and Treatment in Prisons: Lessons Learned from Australia Alex Thompson, University of Melbourne, Australia		
15.55 - 16.15	Enhancing Access to HCV Testing and Treatment Among People Who Use Drugs: Lessons from Brazil Francisco Inácio Bastos, Oswaldo Cruz Foundation, Brazil	15.55 - 16.15	Public Policies in PWID in Prisons and Others Context. Catalonia Experience Joan Colom, Public Health Agency of Catalonia, Autonomous Government of Catalonia, Spain		
16.15 - 16.30	Questions & Discussion	16.15 - 16.30	Questions & Discussion		
16.30 - 17.10	Session Z: Reports and Symposium Closing Room: Sala I + II Chairs: Ricardo Baptiste Leite and Julie Bruneau				
16.30 - 16.40	Policy & Epidemiology Rapporteur Natasha Martin, University of California, United States				
16.40 - 16.50	Linkage to Care & Treatment Rapporteur Alisa Pedrana, Burnet Institute, Australia				
16.50 - 17.00	Models of Care Rapporteur Anne Øvrehus, Rigshospitalet, Denmark				
17.00 - 17.10	Community Rapporteur Annie Madden, Centre for Social Research in Health, University of New South Wales, Australia				
17.10 - 17.15	Symposium Closing and Introduction of Upcoming Conference				